Pfizer gets mixed results against IPP claims
The state antitrust claims brought by a class of indirect purchasers of Pfizer’s cholesterol medication are not pre-empted by federal patent law, a New Jersey federal judge has ruled – but state procedural laws impede some of the claims.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10